U.S. Markets closed

Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?

ALLISON GATLIN
Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?

Seattle Genetics stock toppled Friday after the biotech met expectations for fourth-quarter sales of cancer treatment Adcetris, but issued soft 2019 guidance for its only approved drug.